Introduction
Gene therapy for the central nervous system is a promising approach to treat central nervous system diseases. In fact, novel gene therapy has been tried clinically for glioblastoma, 1, 2 Parkinson's disease, 3 and Canavan's disease. 4 In these trials, adenovirus and adeno-associated virus (AAV) were commonly used. However, there are serious safety problems in the case of viral vectors, such as immunogenicity, 5 delayed demyelination, 6 and difficulties in the preparation of a high titer of virus. 7 Since naked plasmid DNA is safe and easy to handle as compared to viral vectors, intramuscular injection of naked plasmid DNA of angiogenic growth factors such as vascular growth factor (VEGF) has been used clinically for the treatment of ischemic cardiovascular disease. 8, 9 Although some researchers have tried to apply direct injection of naked plasmid DNA into the brain, 10 ,11 the transfection efficiency was quite low 10 and a large amount of naked plasmid DNA was required to produce the target protein. 11 Recently, ultrasound-mediated gene transfer has been reported to augment the transfection efficiency and facilitate local gene expression. 12 Interestingly, gene transfer into the fetal central nervous system was successfully achieved by intrauterine injection with microbubble-enhanced ultrasound. 13 Compared to other viral vectors, there are some theoretical advantages including safety, simplicity of preparation, and local gene transfer. Thus, we focused on the development of gene transfer using naked plasmid DNA with an ultrasound or microbubble-enhanced ultrasound method. In the present study, we investigated the possibility of improving plasmid DNA-based gene transfer into the rat brain.
Results

Gene transfer via cisterna magna
First, we measured luciferase activity in the brainstem and cerebellum after injection of the luciferase gene into the cisterna magna (Figure 1a-c) . Although luciferase activity could be detected following injection of naked DNA alone, it was very low (Figure 2a) . Insonation without microbubbles, Optison, after injection of naked DNA showed a tendency for an increase in luciferase activity. As expected, luciferase activity was markedly enhanced by the addition of 25% Optison and ultrasound (Figure 2a , Po0.05), while addition of Optison alone without insonation did not affect luciferase activity. Efficient plasmid DNA transfer into central nervous system M Shimamura et al
Although an increase in luciferase activity by addition of 6.25, 12.5, or 50% Optison was also observed, the most effective dose was 25% (Figure 2a ). An increase in intensity of ultrasound also increased luciferase activity. An intensity of ultrasound of 5 W/cm 2 was adequate for high transfection efficiency (Figure 2b ). In addition, an increase in the exposure time of ultrasound up to 10 s enhanced the transfection efficiency (Figure 2c ). According to these results, the following experiments were performed under the optimal conditions of 25% Optison, 10 s duration, and 5 W/cm 2 . Unexpectedly, the period of expression of the transgene was relatively short, and at 7 days after transfection, luciferase activity had almost returned to an undetectable level (Figure 2d ).
To examine which cells could be transfected, we transfected the Venus gene into the cisterna magna. In contrast to previous data using vectors such as adenovirus, gene expression was limited to the brainstem and cerebellum, where insonation was performed ( Figure  3d ). There was no gene expression in the cerebral surface (Figure 3b) , striatum, or choroid plexus in the lateral ventricle ( Figure 3c ). Coronal sections of the brainstem showed readily detectable fluorescence of Venus in meningeal cells in the pia mater and arachnoid membrane (Figure 3e and f). Consistent with the expression of the Venus gene, luciferase activity was also detected only in the brainstem and cerebellum (Figure 4 ).
Gene transfer into striatum
Next, the luciferase gene was directly injected into the striatum (Figure 1d and e). Although luciferase expression was detected following injection of the naked luciferase gene alone (Figure 5a ), it was very low. The expression was enhanced about three-fold by addition of ultrasound, and about 10-fold by the addition of 25% Optison and ultrasound (Figure 5a , Po0.01). Since there could be strong absorption of ultrasound by the cranium, we further evaluated the optimal ultrasound conditions. Luciferase activity was maximal at 5 W/cm 2 ( Figure 5b ) and an exposure duration of 10 s (Figure 5c ). According to these results, the following experiments were performed using the optimal ultrasound conditions of 5 W/cm 2 and 10 s duration. Gene expression was observed at least 14 days after injection, which was different from the result of intracisternal injection (Figure 5d ). Then, we injected the Venus gene (50 mg) to clarify the transfectable cells. Transfected cells could not be detected at the injection site with naked plasmid DNA alone. In contrast, gene expression was successfully detected at the injection site using microbubble-enhanced ultrasound ( Figure  6a ). Immunohistochemical staining for NeuN revealed that the transfected cells were not neurons (Figure 6c ).
Safety evaluation
The safety of Optison and ultrasound for gene transfer in the CNS is a critical issue. Since previous studies showed destruction of the blood-brain barrier (BBB) several hours after injection of Optison into the carotid artery 14 or insonation after intravenous injection of Optison, 15 we carefully evaluated the safety aspect of the present gene transfer method. We first evaluated the change in body weight, tissue damage by hematoxylin and eosin (HE) staining, and destruction of the BBB by microangiography using albumin-fluorescein isothiocyanate (FITCalbumin), 16 as the microbubble-enhanced ultrasound Local gene expression produced by plasmid DNA transfer using microbubble-enhanced ultrasound as assessed by luciferase expression. Luciferase activity was measured in the brainstem and cerebellum, left hemisphere, right hemisphere, and olfactory bulb at 1 day after transfection. Gene expression was limited to the brainstem and cerebellum, which were insonated. BS: brainstem and cerebellum; LH: left hemisphere; RH: right hemisphere; OB: olfactory bulb. **Po0.01. n ¼ 4 for each group.
Efficient plasmid DNA transfer into central nervous system M Shimamura et al method achieved high transfection efficiency via a transient change in the cell membrane. 12, 13 Although body weight was decreased temporarily after each treatment, there was no significant difference among the groups (Figure 7 ). There was no histological change or leakage of FITC-albumin in the brainstem and cerebellum after intracisternal injection and insonation (Figures 8a-c and 9a-c) . Although there was hemorrhage at the injection site with intrastriatal injection, the damage was not worsened by Optison or ultrasound (Figure 8d-f) . The damage had not extended at least 28 days after injection (Figure 8f ). There was slight leakage of FITC-albumin at the injection site (dim green area around vessels), but microbubble-enhanced ultrasound did not worsen the leakage (Figure 9d-f) . No behavioral abnormality was observed.
Discussion
The most critical aspect of human gene therapy is the safety of vectors, although the efficiency of transfection Efficient plasmid DNA transfer into central nervous system M Shimamura et al into target organs is also important. Recent clinical trials of gene therapy using viral vectors revealed serious problems such as immunogenicity. 5, 17 From this viewpoint, application of naked plasmid DNA seems most attractive, as plasmid DNA is very safe as compared to other vectors. However, extremely low transfection efficiency has limited its utility. 10, 12 To overcome this problem, we focused on the application of ultrasound, as enhancement of transfection efficiency using ultrasound has been reported in various tissues such as cardiac muscle, 18 skeletal muscle, 19 carotid artery, 12 and the fetus. 13 Ultrasound-mediated plasmid DNA transfection enhances transfection efficiency, since ultrasound induces porosity of the cell membrane. 20 Nevertheless, the increased efficiency may still not be enough. Thus, we further modified ultrasound-mediated plasmid DNA transfection using echo-contrast microbubbles. Indeed, the efficiency of plasmid DNA transfection into artery as well as skeletal muscle using ultrasound was reported to be markedly improved by echo-contrast microbubbles, Optison. 12, 19 The increase in transfection efficiency might be due to transient holes in the cell membrane produced by the spreading of bubbles. 12 However, different from other tissues, application of insonation to the adult brain is not easy because of the thick bone of the skull. Although it is well known that pulsed transcranial ultrasound at low frequencies less than 2 MHz can penetrate the human skull and is used to estimate blood flow in the major cerebral vessels, intracerebral ultrasound intensity is thought to be attenuated by the thick skull. 21 Thus, we initially applied this method to the brainstem via the cerebrospinal fluid (CSF) in the cisterna magna, as there is a large window in the bone. As expected, the microbubble-enhanced ultrasound method resulted in marked enhancement of the transfection efficiency as compared to naked plasmid DNA alone. In contrast to previous data using vectors such as adenovirus 22 or HVJ-envelope vector, 23 gene expression was limited to the insonated sites with intracisternal injection. Using the microbubble-enhanced ultrasound method, the transfected cells were mainly meningeal cells, but not neurons or glia. Although we could not clarify the reason why the transfected cells were limited to meningeal cells, one possible reason is that the mixture of naked DNA and Optison might not penetrate into the cerebral parenchyma. Unexpectedly, the span of gene expression by intracisternal injection was shorter than a week. Further studies are needed to achieve longer gene expression.
When naked DNA was injected into the striatum instead of CSF, the transfected cells were mainly glial cells and not neurons, consistent with a previous report. 11 Since glial cells are important for neuronal survival via the secretion of various neurotrophic factors such as fibroblast growth factor (FGF) and hepatocyte growth factor (HGF), 24 gene transfer of neurotrophic factors to glial cells might promote survival of neurons in neurodegenerative diseases such as Parkinson's disease. Alternatively, as a recent report showed that delivery of recombinant GDNF directly into the putamen of five Parkinson's disease patients in a phase I safety trial produced functional improvement, 25 gene transfer might allow long-term production of neuroprotective growth factors, thus resulting in a better outcome. 26 Indeed, gene therapy for Parkinson's disease in animal models also induced functional recovery using an AAV vector 27 or lentiviral vector, 28 although these vectors have several major problems such as immunogenicity. These diseases might be targeted using the microbubble-enhanced ultrasound method, as naked plasmid DNA is much safer and easier to handle.
Although gene transfer using microbubble-enhanced ultrasound was effective, there are some limitations of the present study. First, the effective intensity of ultrasound used in the present study (2 or 5 W/cm 2 ) was higher than that of commonly used 1 MHz diagnostic ultrasound in the brain (0.5 W/cm 2 ). While there was no significant adverse effect of Optison and ultrasound on histological findings and BBB function at the injection site, the possibility of hemorrhage, BBB destruction, or an inflammatory response in other regions could not be completely excluded. Also, the possibility of damage to bone and soft tissue has not been excluded, since they were not evaluated in the present study. Since 185 kHz ultrasound insonation (2 W/cm 2 ) was reported to potentiate transcranial ultrasound-improved thrombolysis without tissue damage, 29 the ultrasound parameters such as frequency still need to be optimized. Second, we did not examine other echo contrast microbubbles such as Levovist, since they were reported not to enhance the transfer efficiency into cultured human vascular smooth muscle cells and endothelial cells. 12 However, as the biological conditions might differ between in vivo and in vitro or among tissues, further studies are necessary to investigate which kind of echo contrast microbubbles is best. Third, as we did not examine lower (6.25 or 12.5%) or higher doses (50%) of Optison with other conditions of ultrasound, further studies are necessary to clarify the optimal combination of Optison and ultrasound. Fourth, we dissolved a large amount of plasmid DNA in TE buffer, which is a hypo-osmolar solution and known to be toxic to the CNS. The solvent and amount of plasmid DNA need to be optimized for clinical use in the future.
Overall, the present study demonstrated a safe and efficient method of nonviral gene transfer into the adult central nervous system. As no significant body weight loss, BBB dysfunction, or histological change was observed throughout the experimental period, these data clearly demonstrate the clinical utility of a therapeutic strategy based on plasmid DNA-mediated transfer. What is the clinical relevance of a highly efficient gene transfer method based on plasmid DNA using ultrasound with Optison? First, it is possible to decrease the amount of plasmid DNA, thereby decreasing the potential side effects and cost. Second, it is possible to achieve high transfection efficiency without a viral vector. Avoiding a viral gene transfer method such as by use of an adenovirus may increase the safety of gene therapy and extend its application to a wide variety of targeted diseases. Third, further modification of delivery tools such as a catheter with ultrasound may expand the utility of the present modification to transfection into the adult brain. Although the achieved expression of the transgene was still not particularly high in the present study, more effective expression of transgene might be achieved by optimizing these factors.
Materials and methods
Plasmid DNA pCMV-luciferase-GL3 (pcLuc-GL3: 7.4 kb) was constructed by cloning the luciferase gene from the pGL3-promoter vector (Promega Corp., Madison, WI, USA) into pcDNA3 (5.4 kb) (Invitrogen, San Diego, CA, USA) at the HindIII and BamHI sites. Plasmid DNA was purified with a QIAGEN plasmid isolation kit (Hilden, Germany). Venus/pCS2 (4.1 kb) was constructed by insertion of the CMV promoter into the Venus gene at the BamHI and EcoRI sites in pCS2. Venus/pCS2 was donated by Dr Miyawaki 30 (Laboratory for Cell Function For intrastriatal injection, a total volume of 6 ml containing 50 mg plasmid and 1.5 ml Optison was used.
In vivo gene transfer in normal rats
Male Wistar rats (230-260 g; Charles River Japan, Atsugi, Japan) were used in this study. All procedures were conducted in accordance with Osaka University guidelines. Rats were anesthetized by intraperitoneal injection of a mixture of ketamine (Sankyo, Tokyo, Japan) and xylazine (Bayer, Tokyo, Japan). For infusion into the subarachnoid space, the head of each animal was fixed in a prone position, and the atlanto-occipital membrane was exposed through an occipitocerebral midline incision. A stainless-steel cannula (27 gauge; Beckton Dickinson) was introduced into the cisterna magna (subarachnoid space). Plasmid DNA solution was infused at 50 ml/min using an injector (IM-3, Narishige Scientific Instrument Laboratory, Tokyo, Japan) after removing 100 ml CSF. Then, animals were exposed to ultrasound from the injection site or temporal bone (Figure 1a-c) .
For infusion into the striatum, animals were placed in a stereotactic frame (Narishige Scientific Instrument Laboratory, Tokyo, Japan) with the skull exposed. A stainless-steel cannula (33 gauge) was introduced into the striatum (0.2 mm anterior to the bregma, 3.0 mm lateral to the midline, and 5.0 mm below the skull surface). Plasmid DNA solution was injected at 2.0 ml/ min using the injector. Rats were kept in the same position for 3 min to avoid loss of plasmid by backflow. Then, the animals were insonated from the parietal bone (Figure 1d and e) .
The ultrasound-emitting transducer used in the present study was an Ultax UX-301 (Celcom Inc., Fukuoka, Japan) with contact gel. The ultrasound parameters were as described previously, 12, 13 with minor modifications: the transducer diameter was 29 mm, the central frequency was 1 MHz continuous wave (CW), the duty cycle was 26% (on cycles/off cycles ¼ 26/74, pulse repetition frequency ¼ 2 Hz), the intensity was up to 5 W/cm 2 , and acoustic pressure was 0.55 MPa. Animals were exposed once in each experiment immediately after injection of naked DNA.
Assay for luciferase activity
Animals transfected with the luciferase gene were killed under anesthesia at 24 h after transfection. Tissues were harvested and placed individually in FALCON 50 ml tubes. Luciferase activity assay was performed as described previously. 31 Luciferase levels were normalized by determining the protein concentrations of the tissue extracts. 31 Luciferase activity was expressed as relative light units (RLU) per gram of tissue protein. To examine the efficacy of ultrasound-mediated gene transfer via the subarachnoid space, we divided the brain into brain stem and cerebellum, left hemisphere, right hemisphere, and olfactory bulb. For gene transfer after intrastriatal injection, the right hemisphere (injected hemisphere) was cut at 3.0 mm anterior to the bregma and 3.0 mm posterior to the bregma, after division of the brain into left and right hemispheres.
Determination of fluorescence of Venus and immunohistochemical staining
At 3 days after transfection, animals were killed by perfusion with 150 ml physiological saline, followed by 200 ml 4% paraformaldehyde in physiological saline. The brain was removed and fixed in the same fixative for 16 h. The brain was sectioned at 40 mm on a vibratome. For immunohistochemical staining, free-floating sections were incubated in 0.1% Triton X-100, 3% normal goat serum, and anti-NeuN (1:1000, Chemicon, Temecula, CA, USA) after blocking, followed by anti-rabbit fluorescent antibody (1:1000, Alexa Flour 546-conjugated goat antimouse IgG, Molecular Probes, OR, USA). The sections were mounted with VECTA SHIELD (Vector Laboratories, Burlingame, CA, USA). Expression of Venus and immunohistochemical staining were examined under a confocal laser microscope (Bio-Rad, Hercules, CA, USA).
Histological staining
To investigate tissue damage, animals were killed by perfusion with 150 ml physiological saline 4 h or 28 days after each treatment. The brain was removed and fixed in the same fixative for 24 h and embedded in paraffin. Sections were cut at 8 mm at 11.6, 12.6, 13.6, 14.6, and 15.6 mm posterior to the bregma in the case of intracisternal injection or at the injection site in the case of intrastriatal injection, and then subjected to hematoxylin and eosin staining. To evaluate BBB function, we used a recently developed microangiographic technique. 16 This technique allows evaluation of BBB function as well as vascular pattern. Briefly, fluorescent albumin solution was prepared by reconstituting 500 mg bovine desiccate albumin-fluorescein isothiocyanate (SigmaAldrich, USA) in 50 ml PBS. The solution was injected via the jugular vein at a rate of 1 ml/min (10 ml/kg) 4 h after treatment. The same amount of blood was withdrawn before the injection to avoid systemic blood pressure elevation. The brain was fixed in 10% formalin solution and then cryoprotected. The brain was cut in the coronal plane at 50 mm using a freezing microtome and mounted with VECTA SHIELD. We set the region of interest (ROI) at the cerebellum and medulla oblongata or striatum. Five consecutive sections in each rat were observed using a confocal laser microscope (Bio-Rad). BBB leakage could be determined by visualization of albumin. 16 
